The small-cap biotech featured in today’s article has been on a wild trading ride in recent days, having surged 1,600% in two days on enthusiasm for its immunotherapy treatment for breast cancer, clinical trial results for which demonstrate 0% recurrence of the disease at a median of five years in patients who received the treatment following surgery and Herceptin treatment.
“These are five stocks for very aggressive investors looking to get share-count leverage with stocks that have sizable upside potential,” declares the author of today’s… Read More »5 Aggressive Tech Plays Under $10
November saw the FDA grant its first emergency use approval for an at-home, self-collected nasal swab test for COVID-19 and approve the first drugs for… Read More »These Biotechs Are Awaiting FDA Rulings In December
With potential COVID-19 vaccines and therapeutics garnering most of the attention this year in the biotech space, the biotech stock featured in today’s article, which has “a unique approach to the business of drug development” for genetic diseases, has been flying under the radar.
Hated stocks and biotech are the best bets right now.
“These are five stocks for very aggressive investors looking to get share-count leverage with stocks that have sizable upside potential.”
Among the three stocks highlighted in today’s article where analysts at RBC see upside potential over 100% – and which have all earned “Strong Buy” consensus analyst ratings – is “a pharmaceutical company with a unique niche.
Which developmental-stage biotechs have the potential to beat the difficult odds and successfully get their novel drugs to market?
What is this investment opportunity that seems to check all the boxes?
Of the two “best of both worlds” biotech stocks highlighted in today’s article – “companies with both solid drug-development track records and potential COVID-19 vaccine tailwinds that could net them each significant profits for their role over the next several years”.